Introduction {#s1}
============

*Talaromyces marneffei* (previously known as *Penicillium marneffei*) is a pathogenic fungus indigenous to Southeast Asia ([@B1]--[@B5]). Before the human immunodeficiency virus (HIV) epidemic, *T. marneffei* was an extremely rare pathogen in humans ([@B1]). Since the late 1980s, talaromycosis emerged as a clinically important opportunistic infection following the exponential growth in the incidence of HIV in Southeast Asia, especially in Northern Thailand, Vietnam, Guangxi, and Guangdong in Southern China ([@B2]--[@B6]). An increasing number of cases have also been reported in Myanmar, Laos, Cambodia, Singapore, Malaysia, Indonesia, and northeastern India ([@B7], [@B8]). *T. marneffei* infection is classified as an acquired immunodeficiency syndrome (AIDS)-defining illness and listed as one of the HIV clinical stage 4 conditions ([@B6]). The trend of *T. marneffei* infection closely paralleled that of HIV, and in areas where reduction of HIV transmission and availability of highly active antiretroviral therapy (HAART) have improved, a decrease in the prevalence of *T. marneffei* infection has been observed ([@B9], [@B10]). A similar trend is also observed in endemic mycoses caused by other thermally dimorphic fungi such as coccidioidomycosis and histoplasmosis ([@B11], [@B12]). The close relationship between disease manifestation and severity with CD4+ cell count confirms the central importance of cell-mediated immunity against endemic fungi.

While the vast majority of talaromycosis were reported in patients with AIDS, a smaller proportion of cases were described in patients with hematological malignancies, autoimmune diseases, and diabetes mellitus and renal or hematopoietic stem cell transplant recipients ([@B13], [@B14]). Autoantibody against IFN-γ has been reported to be associated with adult-onset immunodeficiency in patients of Asian ethnicity, resulting in predisposition to talaromycosis, melioidosis, salmonellosis, and non-tuberculous mycobacterial infections ([@B15]--[@B20]). Talaromycosis in otherwise healthy children is uncommon. We performed a systematic literature review of 509 reports on human *T. marneffei* infection published between 1950 and 2011, and identified 32 patients aged 3 months to 16 years with no known HIV infection. Twenty-four patients (75%) had disseminated disease, and 55% died of talaromycosis. Eight patients, all reported prior to 2010, had some forms of immunodeficiencies which were not genetically defined (hypogammaglobulinemia, CD4 lymphopenia, common variable immunodeficiency, Kostmann syndrome, and clinically probable X-linked hyper-IgM syndrome) or blood disorders such as aplastic anemia. Four others had abnormal immune functions while immune evaluation was not performed for the rest ([@B21]). In 2014, we discovered gain-of-function (GOF) STAT1 disorder as the underlying cause of disseminated talaromycosis in 3 pediatric patients in Hong Kong ([@B22]). Recently, primary immunodeficiencies (PID) in HIV-negative children with *T. marneffei* infection have been increasingly recognized, including CD40L deficiency and autosomal dominant (AD) hyper-IgE syndrome ([@B23]--[@B29]). However, talaromycosis as an indicator of underlying PID in HIV-negative children is still under-recognized, as diagnostic immunological evaluations remained limited in many recently published cases ([@B30]--[@B34]).

The close epidemiological relationship between HIV and *T. marneffei*, and the fact that talaromycosis is an AIDS-defining illness ([@B6]) suggests that individuals who are HIV negative and without secondary immunodeficiencies may have underlying immune defects that are unrecognized. There is a need to adopt a systematic approach to evaluate HIV-negative individuals with talaromycosis, by performing stepwise immunological investigations to guide confirmatory genetic tests, targeting on disorders affecting IFN-γ mediated crosstalk between phagocytic cells and T-lymphocytes, and signaling pathways involved in T-helper 1 (Th1) and Th17 differentiation. In this article, we illustrate how flow cytometric evaluation can be incorporated into a simple and rapid diagnostic algorithm for patients with disseminated talaromycosis requiring immunological investigations.

Methodology {#s2}
===========

Patients
--------

The Asian Primary Immunodeficiency (APID) Network was established by the Department of Pediatrics and Adolescent Medicine, The University of Hong Kong ([@B35]). Since 2001, 1,599 patients with suspected PID from more than 90 centers in 13 countries and regions in Asia were referred to the APID Network for genetic studies. Among them, eight patients had *T. marneffei* infection including four from Hong Kong, two from Southern China and two from Northern Thailand. Clinical features and immunological parameters were retrieved from the database. Consent for genetic diagnosis and functional study was obtained from parents, and the study was approved by the Institutional Review Board of The University of Hong Kong/Hospital Authority Hong Kong West Cluster.

Flow Cytometric Evaluation of CD40 Ligand (CD40L) Expression
------------------------------------------------------------

Detailed methodology was previously reported by An et al. ([@B36]) and Du et al. ([@B29]). Briefly, peripheral blood mononuclear cells (PBMC) obtained from patients and healthy controls were isolated by ficoll-hypaque density gradient centrifugation. At least 1 × 10^6^ PBMCs were cultured at 37°C for 4 h at 500 μl RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum (FCS), and activated by 50 ng/ml phorbol myristate acetate (PMA) and 500 ng/ml ionomycin (Sigma, Shanghai, China). Cells were collected, washed and incubated with PerCP-Cy5.5-conjugated anti-human CD3 (mouse IgG1, κ, clone OKT3), FITC-conjugated anti-human CD8 (mouse IgG1, κ, clone RPA-T8), and PE-conjugated anti-human CD154 antibody (mouse IgG1, κ, clone 24-31) or PE-conjugated isotype control (IgG1, clone P3). All antibodies were obtained from eBioscience (San Diego, CA, USA). Flow cytometric analysis was performed (FACSCanto II, BD Biosciences), gating on live cells determined by scatter characteristics. Data was analyzed using FlowJo software (Tree Star, Ashland, OR, USA). The percentage of CD3+CD8-CD154+ cells was determined by gating on dot-plot histograms and comparing with cells stained with isotype control reagents.

Flow Cytometric Quantification of STAT1 Phosphorylation
-------------------------------------------------------

Detailed methodology was previously published by our group ([@B22]). 10^6^ PBMCs were stimulated with recombinant human IFN-α (40,000 IU/ml) or IFN-γ (5,000 IU/ml) for 20 or 30 min as indicated. To study the kinetics of STAT1 dephosphorylation, cells were further treated with staurosporine (500 nM) for 30 min. Cells were washed and stained with FITC-conjugated anti-human CD3 and pacific-blue-conjugated anti-human CD14. This was followed by fixation with BD Phosflow™ Fix Buffer I and permeabilization in BD Phosflow™ Perm Buffer III. After wash, cells were stained with AlexaFluor® 647-conjugated anti-human STAT1 (pY701) for intracellular phosphorylated STAT1 (pSTAT1). The percentage of intracellular pSTAT1 expression and mean fluorescent intensity (MFI) in CD3+ T-cells and CD14+ monocytes were determined by using flow cytometry and analyzed by FlowJo (version: 8.8.2). Gating strategy is shown in [Supplementary Figure 1](#SM2){ref-type="supplementary-material"}.

Sanger Sequencing
-----------------

Genomic DNA was isolated from peripheral blood obtained from the subjects. Fiffty nanograms DNA were added to sequencing primers for human *STAT1, CD40LG*, and *IFNGR1* genes for sequence analysis (see [Supplementary Table 1](#SM1){ref-type="supplementary-material"} for primer sequences) using Applied Biosystems 3730xl DNA Analyzer. Sequence analysis with reference sequence of the corresponding genes was performed using the National Center for Biotechnology Information program Basic Local Alignment Search Tool (<https://blast.ncbi.nlm.nih.gov/Blast.cgi/>).

Whole Exome Sequencing Procedure
--------------------------------

Three microgram of genomic DNA extracted from the patient\'s PBMCs for exon capture by using Agilent SureSelect Human All Exon 50 Mb and library preparation, according to standard procedures. WES was performed using Illumina HiSeq 2000 (Illumina, Inc., San Diego, CA 92122 USA) on genomic DNA enriched for exonic fragments using Agilent SureSelect V3 (Agilent technologies, Santa Clara, CA 95051 USA). The data were processed using GATK. Briefly, paired-end reads were mapped to human reference genome (GRCh37/hg19) using Burrows-Wheeler Aligner (<http://bio-bwa.sourceforge.net/>). Picard was used to mark duplicated reads and Realigner Target Creator and Base Recalibrator of GATK were used for realignment and base quality recalibration. Single nucleotide variants (SNVs) were called by using GATK (<http://www.broadinstitute.org/gatk/>), and indel were identified by using GATKindel, Dindel (<http://www.sanger.ac.uk/resources/software/dindel/>), and Pindel (<https://trac.nbic.nl/pindel/>). SNVs with minor allele frequency of 1% are considered as polymorphism. SNV calls with a quality phred score of more than 30, mapping quality phred score of more than 10, and coverage depth of more than 10 were kept for further analysis. Mutations were annotated using annovar. Of the SNV calls, their population frequency in dbSNP, 1000 Genome Project, NHLBI Exome Sequencing Project (ESP) ESP6500 data set (<http://evs.gs.washington.edu/EVS/>), and an internal database on exome sequencing was examined and relatively common variants considered unlikely to be related to the disease phenotype were excluded from further consideration. Potential functional impact of the missense mutations was also evaluated by algorithms including SIFT, PolyPhen2, LJB_PolyP, LJB_MutationTaster, LJB_LRT, and those considered to be unlikely to have a strong functional impact on the protein structure and function were also removed from further consideration. Variants that were considered high (frame shift mutations, splicing site mutations, start/stop gains and losses) and moderate functional impact (missense substitutions and non-frame shift insertion deletions) were further considered. The putative disease-causing variants were confirmed by Sanger sequencing.

Results {#s3}
=======

Family 1
--------

A 29-month old boy (F1) was admitted because of persistent fever for 1 month and neck mass for 10 days. Chest X-ray showed pneumonic changes. Cervical lymph node biopsy and endobronchial biopsy both yielded *T. marneffei*. Blood culture was positive for *T. marneffei* and *Staphylococcus epidermidis*. He has a past history of recurrent infections since 13 months of age. He received BCG vaccination at birth, and developed left axillary lymphadenitis which resolved spontaneously. His complete blood count was unremarkable. Lymphocyte subset showed reduced T and NK cells, and Immunoglobulin profile showed reduced serum IgG (431 mg/dl), lowish IgA (44 mg/dl), and IgM (62mg/dl; [Table 1](#T1){ref-type="table"}). HIV serology was negative. CD40L expression on CD3+ T-cells activated by phorbol myristate acetate (PMA) and ionomycin was absent in the patient, and normal in both parents ([Figure 1](#F1){ref-type="fig"}). X-linked hyper-IgM syndrome was genetically confirmed by the identification of a mutation in the *TNFSF5* (*CD40L*) gene, g.IVS1+1G\>A predictive of aberrant splicing ([Figure 2](#F2){ref-type="fig"}). The episode of disseminated talaromycosis was treated with voriconazole for 4 months. He was put on trimethoprim sulfamethoxazole prophylaxis and continued with monthly immunoglobulin replacement. Two years later, he developed persistent sinusitis and culture from nasal secretions again yielded *T. marneffei*. He was treated with a short course of voriconazole.

###### 

Hematological and immunological parameters.

                                    **F1**                  **F2**                  **F3**                    **F4**                    **F5.1**                  **F6.1**
  --------------------------------- ----------------------- ----------------------- ------------------------- ------------------------- ------------------------- ---------------
  Hb (g/dl)                         12.0                    10.5                    10.3                      9.8                       8.8                       6.9
  **Full Blood Count**                                                                                                                                            
     WCC (× 10^9^/l)                2.37                    6.3                     12.81                     6.5                       3.2                       24.5
     ANC (× 10^9^/l)                0.87                    4.86                    10.71                     2.86                      N/A                       18.6
     ALC (× 10^9^/l)                1.28                    0.84                    0.89                      2.87                      N/A                       4.94
     PLT (× 10^9^/l)                367                     308                     229                       297                       N/A                       24
     ESR (mm/h)                     44                      75                      104                       89                        N/A                       N/A
     CRP (mg/l)                     3                       24.5                    6.75                      5.67                      N/A                       N/A
  **Serum Ig**                                                                                                                                                    
     IgG (g/l)                      4.3 (6.76--13.49)       26.8 (5.37--16.82)      32.1 (7.24--13.8)         11.13 (7.24--13.8)        N/A                       18.8
     IgA (g/l)                      0.44 (0.63--2.34)       4.09 (0.74--2.61)       3.30 (0.68--2.29)         0.74 (0.68--2.29)         N/A                       2.43
     IgM (g/l)                      0.62 (0.64--2.37)       1.23 (0.40--1.95)       0.97 (0.88--2.75)         1.59 (0.88--2.75)         N/A                       2.61
  **Lymphocyte Subset**                                                                                                                                           
     CD3+ (/μl, %)                  706 (55.2)              841 (78.1)              833 (76.2)                1832 (63.7)               N/A                       3276 (66.2%)
     Normal range for age and sex   1,500--2,900 (62--70)   1,100--2,200 (56--72)   1,300--2,200 (64--72.5)   1,300--2,200 (64--72.5)                             (50--81)
     CD4+ (/μl, %)                  454 (35.5)              297 (27.6)              375 (34.3)                897 (31.2)                93 (29%)                  2,153 (43.5)
     Normal range for age and sex   1,000--2,100 (29--40)   600--1,600 (27--34)     600--1,100 (29.5--35.5)   600--1,100 (29.5--35.5)   600--1,100 (29.5--35.5)   (22-50)
     CD8+ (/μl, %)                  228 (17.8)              400 (37.1)              392 (35.8)                701 (24.4)                138 (43%)                 1,064 (21.5%)
     Normal range for age and sex   700--1,100 (19--25)     500--1,200 (23--30)     500--1,000 (24--33.5)     500--1,000 (24--33.5)     500--1,200 (23--30)       (18--44%)
     CD19+ (/μl, %)                 512 (40.0)              158 (14.7)              189 (17.2)                879 (30.6)                 Normal                   1168 (23.6%)
     Normal range for age and sex   500--1,200 (18.5--28)   200--600 (15--20)       300--500 (14--21)         300--500 (14--21)         200--600 (15--20)         (7--27%)
     CD16/56+ (/μl, %)              40 (3.1)                52 (4.9)                25 (2.3)                  101 (3.5)                 N/A                       190 (9.9%)
     Normal range for age and sex   300--600 (9--195)       300--600 (11--24)       300--500 (11--23)         300--500 (11--23)                                   (2--40%)

![CD40L expression in patient F1 and his parents. Peripheral blood mononuclear cells (PBMCs) were activated by phorbol myristate acetate (PMA) and ionomycin, followed by immunostaining with anti-CD3-PerCP-Cy5.5, anti-CD8-FITC, and anti-CD154-PE antibody. Flow cytometric analysis was performed gating on CD3+ T-cells. CD3+CD8-CD154+, represented by UL (upper left quadrant), indicated activated T-cells expressing CD40L.](fimmu-10-02189-g0001){#F1}

![**(A)** Pedigrees of Families 1--6. **(B)** Mutations identified in patients with *T. marneffei* infections. (i) Splice site mutation in *TNFSF5* (*CD40L*) in Patient F1; (ii) heterozygous missense mutations in *STAT1* identified in Patients F2 (p.A267V), F3 (p.T288I), F4 (p.L358F), F5.1, and F5.2 (p.M390I); (iii) homozygous mutation in *IFNGR1* identified in Patient F6.2 (p.V61fsX69) and his deceased elder sister (F6.1). Both parents were found to be heterozygous carriers of the mutation.](fimmu-10-02189-g0002){#F2}

At 6 years, he developed fever, cough, stridor and shortness of breath. Laryngoscopy showed vocal cord swelling, and he was subsequently intubated and ventilated for acute upper airway obstruction. Throat swab and sputum yielded positive growth of *T. marneffei*. CT scan showed thickened vocal cord and laryngeal narrowing. There was segmental collapse and consolidation in the left lung, and calcified lymph nodes in the bilateral hilar and mediastinal regions. There was clinical improvement after adding on anti-fungal treatment and he was extubated 3 days later. He completed a 6-week course of voriconazole and had good clinical recovery, and was put on fluconazole prophylaxis. A 10/10 matched-unrelated donor was identified and he is currently prepared for haematopoietic stem cell transplantation.

Family 2, 3, and 4
------------------

We previously reported 3 pediatric patients with *T. marneffei* infection and chronic mucocutaneous candidiasis (CMC) caused by GOF *STAT1* mutations ([@B22]). Briefly, F2 presented with cervical and mediastinal lymphadenopathy at 15 years and fine needle aspiration of the cervical lymph node yielded *T. marneffei*. F3 presented with pneumonia and otitis externa at the age of 7 years. Nasopharyngeal aspirate was positive for influenza A with prolonged carriage. Computed tomography (CT) of the thorax showed mediastinal and hilar lymphadenopathy with multiple thin-walled pulmonary cystic cavities. Bronchoalveolar lavage yielded *T. marneffei* and cytomegalovirus. Ear swab culture was positive for *Candida albicans* and *C. tropicalis*. Both F2 and F3 received amphotericin treatment with good response, and were put on long-term itraconazole prophylaxis without disease recurrence.

F4 presented with fever and cervical lymphadenopathy at 5 years old. Lymph node biopsy yielded *Mycobacterium tuberculosis* and *T. marneffei*. She received anti-tuberculosis treatment and itraconazole with good response. At 16 years old, she developed invasive aspergillosis and haemophagocytic syndrome, and died of massive pulmonary hemorrhage.

Immunological parameters were summarized in [Table 1](#T1){ref-type="table"}. Whole exome sequencing revealed the presence of heterozygous mutation in *STAT1* gene in the coiled-coil domain for F2 (c.800C\>T, p.A267V) and F3 (c.863C\>T, p.T288I), and DNA-binding domain for F4 (c.1074G\>T, p.L358F; [Figure 2](#F2){ref-type="fig"}). PBMCs from these patients showed increased STAT1 phosphorylation toward interferon (IFN)-α and IFN-γ as well as delayed STAT1 dephosphorylation in the presence of staurosporine, indicating that they were GOF mutations.

Family 5
--------

A 9-year old boy (F5.2) was referred for recurrent pneumonia and chronic onychomycosis. Upon inquiry on family history, the boy\'s father (F5.1) has a history of protracted fungal infection in his childhood. The description of his clinical course could be traced back to a case report by Yuen et al. published in 1986, the first report of pediatric disseminated *T. marneffei* infection in Hong Kong ([@B37]). In brief, F5.1 presented with bilateral cervical lymphadenopathy at 10 years old in 1983 and was initially treated with anti-tuberculous drugs. There was progressive enlargement of the cervical lymph nodes complicated by ulceration of the overlying skin and perforation of the hard palate. He was also found to have enlarged mediastinal lymph nodes causing superior vena cava (SVC) obstruction. Tissue from the neck ulcer and axillary lymph node yielded *T. marneffei*. Lymphocyte subset showed profound T-lymphopenia (CD4 93/μl and CD8 138/μl). He was treated with intravenous amphotericin B and oral flucytosine for 3 months with good response. However, 3 years later he presented again with generalized skin lesions, oral ulceration, and recurrence of mediastinal lymphadenopathy. He was treated with amphotericin B for 3 months but shortly after stopping anti-fungal treatment, he had recurrent disease with osteomyelitis involving the left distal radius and ulna, left thumb metacarpus and right tibia ([@B38]). Treatment with amphotericin B was resumed but he experienced severe adverse reactions, which necessitated the switch to oral fluconazole. The disease went into remission after 6 months of fluconazole, which he continued taking for a total of 2 years. He had no further disease recurrence and remained largely asymptomatic. His CD4+ and CD8+ T-cells returned to normal, but he was found to have impaired natural killer (NK) cell cytotoxicity ([@B38]). He had no medical follow-up since the late 1990s.

F5.1 was 40 years old when he was seen in our clinic together with his son. He had classical features of CMC. He had multiple scars in the neck that corresponded to the history of ulcerated cervical lymphadenopathy. He had mild facial puffiness, and the prominent superficial veins in the neck and upper chest were the result of previous SVC obstruction.

PBMCs obtained from the father and son showed increased STAT1 phosphorylation (pSTAT1) toward IFN-α stimulation (MFI = 282 for F5.1 and 296 for F5.2, vs. 153 ± 8.0 in 3 healthy controls, mean ± SEM), as well as reduced STAT1 dephosphorylation in the presence of staurosporine ([Figure 3](#F3){ref-type="fig"}). A heterozygous missense mutation in the DNA binding domain of the *STAT1* gene (c.1170G\>A, p.M390I) was identified by Sanger sequencing ([Figure 2](#F2){ref-type="fig"}). Both patients remained clinically well while on anti-fungal prophylaxis.

![PBMCs were stimulated with IFN-α (40,000 IU/ml) followed by treatment with staurosporine (500 nM) for 30 min, and analyzed for intracellular pSTAT1 expression by gating on CD3+ T-cells. The increase in %pSTAT1^+^ population in stimulated cells relative to unstimulated cells was calculated. **(A)** Representative histograms are shown for Patients F5.1 and F5.2 and 3 healthy controls. **(B)** %pSTAT1^+^ T-cells (i) and mean fluorescent intensity (MFI) (ii) in Patients F5.1 and F5.2 compared with 3 healthy controls. Data expressed as mean ± SEM.](fimmu-10-02189-g0003){#F3}

Family 6
--------

F6.2 is the second child of a family belongs to the Karen ethnic group residing in the Thailand-Myanmar border. His parents are third cousins. His elder sister (F6.1) had disseminated *T. marneffei* infection at 5 months, and died of fulminant Salmonella septicemia at 11 months. She was negative for HIV, and immunological investigations including lymphocyte subset, immunoglobulin levels, and dihydrorhodamine reduction (DHR) was unremarkable. WES revealed a novel homozygous frameshift mutation (c.182dupT, p.V61fsX69) in the *IFNGR1* gene, resulting in a premature stop codon upstream to the segment encoding the transmembrane domain ([Figure 2Biii](#F2){ref-type="fig"}). Parents were heterozygous carriers ([Figure 2A](#F2){ref-type="fig"}). F6.2 developed disseminated BCG and Salmonella septicemia at 2 months of age. At 12 months, he was admitted to Chiang Mai University Hospital for high fever and refusal to stand and walk. Blood culture yielded *T. marneffei* and plain X-ray of his legs showed osteolytic lesion in the left distal tibia. He received amphotericin B for 6 weeks with good treatment response. His daily activities returned to normal and he was put on isoniazid, rifampicin and itraconazole prophylaxis.

In view of the family history, Sanger sequencing of the *IFNGR1* gene was performed which showed that F6.2 had the same homozygous frameshift mutation as his deceased sister. PBMCs obtained from F6.2 showed defective STAT1 phosphorylation toward IFN-γ stimulation in CD14+ monocytes compared with 4 healthy controls ([Figures 4Aii,Bii,Civ](#F4){ref-type="fig"}), while STAT1 phosphorylation toward IFN-α stimulation was preserved in CD3+ T-cells ([Figures 4Ai,Bi,Ci,ii](#F4){ref-type="fig"}), implying defective IFN-γ receptor-mediated signaling.

![Flow cytometric analysis of STAT1 phosphorylation (pSTAT1) in CD3+ T-cells and CD14+ monocytes in response to IFN-α and IFN-γ. Representative flow plots showing % pSTAT1+ cells in **(A)** Patient F6.2 and **(B)** a healthy control. Peripheral blood mononuclear cells (PBMCs) were stimulated with IFN-α (40,000 IU/ml) or IFN-γ (5,000 IU/ml) for 20 or 30 min. Intracellular phosphorylated STAT1 (pSTAT1) was evaluated by gating on CD3+ and CD14+ cells in PBMCs stimulated with IFN-α **(A**i, **B**i**)** and CD14+ cells in PBMCs stimulated with IFN-γ **(A**ii, **B**ii**)**. **(C)** Mean fluorescent intensity (MFI) of pSTAT1 in Patient F6.2 and 4 healthy controls, data expressed as mean ± SEM.](fimmu-10-02189-g0004){#F4}

PIDs in HIV-Negative Children With Talaromycosis and Proposed Diagnostic Algorithm {#s4}
==================================================================================

In addition to the above described patients, 12 cases of pediatric patients with talaromycosis and underlying PIDs were reported in the literature ([@B22]--[@B29]), and they are summarized in [Table 2](#T2){ref-type="table"}. Out of these 19 patients, 13 patients (68%) were below the age of 5 years when they had *T. marneffei* infection. 15 patients (79%) had disseminated talaromycosis and two of them had recurrence. Only one patient died of talaromycosis due to multi-organ failure. PIDs diagnosed included X-linked hyper-IgM syndrome (*n* = 10), AD hyper-IgE syndrome (*n* = 3), AD GOF STAT1 disorder (*n* = 4), and autosomal recessive (AR) IFNγR1 deficiency (*n* = 2).

###### 

Primary Immunodeficiencies reported in HIV-negative children with *T. marneffei* infection.

                                           **Genetic defect**                   **Mutation**                                          **Gender/age, residence**            **Extent of *T. marneffei* infection**                                      **Treatment and outcome**
  ---------------------------------------- ------------------------------------ ----------------------------------------------------- ------------------------------------ --------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  F1                                       CD40L deficiency                     g.IVS1+1G\>A                                          M/29 months, China                   Disseminated, with recurrent disease                                        Disseminated disease reated with voriconazole for 4 months with good response, subsequent recurrence as laryngeal involvement also treated with voriconazole with success
  Kamchaisatian et al. ([@B24])            CD40L deficiency                     Complex mutation in exon 5                            M/14 months, Northeastern Thailand   Disseminated                                                                Treated with amphotericin B for 21 days, followed by itraconzole for 10--12 weeks
  Kamchaisatian et al. ([@B24])            CD40L deficiency                     Not stated                                            M/1 year, Northern Thailand          Pulmonary disease and lymphadenopathy                                       Treated with amphotericin B for 21 days, followed by itraconzole for 10--12 weeks
  Sripa et al. ([@B25])                    CD40L deficiency                     Not stated                                            M/3 years, Thailand                  Pulmonary disease                                                           Itraconazole, good response
  Liu et al. ([@B27]) Du et al. ([@B29])   CD40L deficiency                     g.IVS1-3T\>G                                          M/2 years, China                     Disseminated                                                                Died of multi-organ failure
  Li et al. ([@B23])                       CD40L deficiency                     Not stated                                            M/14 months, China                   Disseminated                                                                Treated with itraconazole for 2 weeks and improved
  Du et al. ([@B29])                       CD40L deficiency                     g.IVS3+1G\>A                                          M/35 months, China                   Disseminated                                                                Responded well to anti-fungal therapy
  Du et al. ([@B29])                       CD40L deficiency                     g.IVS1-1G\>A                                          M/27 months, China                   Disseminated                                                                Lost to follow-up
  Du et al. ([@B29])                       CD40L deficiency                     g.IVS4+1G\>C                                          M/3 years, China                     Disseminated                                                                Responded well to anti-fungal therapy
  Du et al. ([@B29])                       CD40L deficiency                     Large fragment deletion including exon 4 and exon 5   M/13 years, China                    Disseminated                                                                Responded well to anti-fungal therapy
  Ma et al. ([@B26])                       AD Hyper-IgE syndrome (STAT3)        Not stated                                            M/30 years, Hong Kong, China         Pulmonary (co-infection with *Stenotrophomonas maltophilia*)                Treated with amphotericin B, died of respiratory failure due to rapid disease progression
  Lee et al. ([@B22])                      AD Hyper-IgE syndrome (STAT3)        p.D374G                                               F/12 months, China                   Disseminated                                                                Treated with itraconazole with good response
  Fan et al. ([@B28])                      AD Hyper-IgE syndrome (STAT3)        p.K531N                                               M/13 years, China                    Disseminated                                                                Amphotericin B and voriconazole for 2 weeks, followed by itraconzole for 2 months
  F2                                       AD gain-of-function STAT1 disorder   p.A267V                                               M/15 years, Hong Kong, China         Disseminated                                                                Treated with amphotericin B for 6 weeks with good response, followed by itraconazole prophylaxis
  F3                                       AD gain-of-function STAT1 disorder   p.T288I                                               F/7 years, Hong Kong, China          Pulmonary (co-infection with cytomegalovirus)                               Treated with amphotericin B for 6 weeks with good response, followed by itraconazole prophylaxis
  F4                                       AD gain-of-function STAT1 disorder   p.L358F                                               F/5 years, Hong Kong, China          Cervical lymphadenopathy (co-infection with *Mycobacterium tuberculosis*)   Treated with itraconazole and anti-tuberculous treatment with good response
  F5                                       AD gain-of-function STAT1 disorder   p.M390I                                               M/10 years, Hong Kong, China         Disseminated with multiple recurrences                                      Protracted courses of anti-fungal therapy with eventual clearance
  F6.1                                     AR IFNGR1 deficiency                 Homozygous p.V61fsX69                                 F/5 months, Northern Thailand        Disseminated                                                                Treated with amphotericin B for 6 weeks with good response, followed by itraconazole prophylaxis
  F6.2                                     AR IFNGR1 deficiency                 Homozygous p.V61fsX69                                 M/12 months, Northern Thailand       Disseminated                                                                Treated with amphotericin B for 6 weeks with good response, followed by itraconazole prophylaxis

We propose a diagnostic algorithm targeting at the above PIDs for immunological evaluation of HIV-negative children with talaromycosis in whom secondary causes of immunosuppression are excluded ([Figure 5](#F5){ref-type="fig"}). History taking and physical examination should focus on identifying past history or concurrent opportunistic infections including BCG complications and non-tuberculous mycobacteria infections, salmonellosis, *Pneumocystis jiroveci* pneumonia, cryptosporidiosis, severe human herpes virus infections (e.g., varicella zoster virus, cytomegalovirus, and Epstein Barr virus), chronic mucocutaneous candidiasis, onychomycosis, and other invasive fungal infections such as aspergillosis. Recurrent sinopulmonary infections are common in CD40L deficiency and AD GOF STAT1 disorder. Coarse facies, high-arched palate, retention of deciduous teeth, scoliosis, cold abscesses and pneumatoceles are suggestive of AD hyper-IgE syndrome. Detailed family history on recurrent infections, early infant deaths and parental consanguinity should be sought. A basic panel of immunological investigations including immunoglobulin pattern (IgG, IgA, IgM, and IgE) and lymphocyte subset should be performed. Low IgG, low IgA, and normal or high IgM in a male patient raises suspicion for CD40L deficiency and one should proceed with flow cytometric evaluation of CD40L expression. The presence of pneumoatoceles, eosinophilia, and elevated IgE, in the presence of somatic features of AD hyper-IgE syndrome, should prompt genetic confirmation of *STAT3* gene mutation. Defects in interferon-mediated JAK-STAT signaling are evaluated by STAT1 phosphorylation studies by flow cytometry. STAT1 hyperphosphorylation in response to IFN-α or IFN-γ and delayed dephosphorylation in the presence of staurosporine is diagnostic for GOF STAT1 disorder, while absent STAT1 phosphorylation in response to IFN-γ but normal response to IFN-α is suggestive of IFN-γ receptor deficiency. Although endemic mycoses have not been reported in patients with chronic granulomatous disease (CGD), it is reasonable to include nitroblue tetrazolium test (NBT) or dihydrorhodamine test (DHR) as a screening strategy for invasive fungal infections. In older children or teenagers who are otherwise healthy, autoantibodies against IFN-γ should be measured.

![Algorithm for immunological evaluation of pediatric patientswith disseminated *Talaromyces marneffei* infection. AD, autosomal dominant; BCG, Bacille Calmette-Guerin; CMV, cytomegalovirus; EBV, Epstein-Barr virus; GOF, gain-of-function; HIES, hyper-IgE syndrome; NTM, non-tuberculous mycobacteria; pSTAT1, phosphorylated STAT1; VZV, varicella zoster virus; X-HIM, X-linked hyper-IgM syndrome.](fimmu-10-02189-g0005){#F5}

Discussion {#s5}
==========

The mechanism of immune response toward penicilliosis is poorly understood. Human penicilliosis is believed to be initiated by inhalation of conidia which are subsequently phagocytosed by alveolar macrophages. They survive in the intracellular environment of macrophages and develop into the yeast phase. Once established within the macrophages, *T. marneffei* readily disseminates throughout the body causing systemic infection when host immune response is suppressed. Clinically, only the yeast form is found in tissues and peripheral blood ([@B3], [@B39]). Only a few studies on cell mediated immune response toward *T. marneffei* were available in the literature. *T. marneffei* infection is fatal in nude mice or T-cell depleted mice, indicating the importance of T-cell response in the immune defense against *T. marneffei* ([@B40], [@B41]). Fungicidal activity of *T. marneffei* yeast by human and murine macrophages could be enhanced by IFNγ via stimulation of L-arginine-dependent nitric oxide pathway ([@B42]). In mice infected by *T. marneffei*, a Th1-polarized pattern of cytokines (IFN-γ and IL-12) was observed in the spleen, and systemic *T. marneffei* infection was invariably fatal in IFN-γ-knockout mice ([@B43]). The importance of IFN-γ in host defense against T. marneffei is best illustrated by the association of high-titer anti-IFNγ autoantibody with disseminated non-tuberculous mycobacteria (NTM) infection, talaromycosis, histoplasmosis, cryptococcosis, melioidosis, non-typhoidal salmonellosis, and severe varicella zoster virus infections in adults without HIV infection ([@B15]--[@B20]). These infections are typical of advanced AIDS despite the fact that these patients had essentially normal numbers of CD4+ T cells and other lymphocytes ([@B17]). F6.1 and F6.2 were the first cases of invasive mycoses reported in AR IFNγR1 deficiency. Susceptibility to candidiasis and filamentous fungi has not been described in patients with AR IFNγR1 deficiency; instead, histoplasmosis ([@B44]) and coccidioidomycosis ([@B45]) were reported in patients with AD partial IFN-γR1 deficiency residing in endemic regions in the United States. Both patients had disseminated mycoses with lymphadenopathy, pulmonary and skeletal involvement necessitating surgical intervention, and recurrent/refractory disease course requiring prolonged intensive anti-fungal treatment, as well as concomitant NTM infections. Both patients received IFN-γ as an adjunctive treatment that led to clearance of infections. Taken together, it is most likely that IFN-γ plays a critical role in host immunity against dimorphic fungi.

The current understanding about inborn errors of immunity predisposing to talaromycosis is limited. The geographical regions with the highest incidence of *T. marneffei* infections are relatively less developed in terms of PID specialist service. It is likely that many HIV-negative children with talaromycosis have not received thorough immunological investigations, and hence the proportion of such cases with underlying PIDs is unknown. Through our APID Network and literature search, the types of PIDs that have been documented in children with *T. marneffei* infection include CD40L deficiency, AD hyper-IgE syndrome, GOF STAT1 disorder and AD IFN-γR1 deficiency. These PIDs have also been identified in other endemic mycoses including histoplasmosis ([@B44], [@B46]--[@B61]), coccidioidomycosis ([@B45], [@B53], [@B61]--[@B63]) and paracoccidioidomycosis ([@B64]). Such dimorphic fungi have also caused disseminated disease in patients with IL12Rβ1 deficiency ([@B65]--[@B69]). In addition, disseminated histoplasmosis was reported in patients with GATA2 deficiency ([@B52], [@B70]) and NEMO deficiency ([@B52]), mainly in adults. The susceptibility to endemic mycoses in CD40L, NEMO, IL12Rβ1 and IFN-γR1 deficiencies highlights the critical role of IL-12/IFN-γ crosstalk in macrophage activation and killing of these dimorphic fungi. On the other hand, impaired Th17 response in GOF STAT1 defect and AD hyper-IgE syndrome leads to CMC and invasive fungal infections caused by filamentous and dimorphic fungal pathogens. In fact, IL12Rβ1, NEMO, CD40L, and IFNγR1 deficiencies also result in impaired Th17 generation from naïve T-cells which likely contribute to susceptibility to fungal infection ([@B71]). There is a gap of knowledge in Th17-mediated cellular response against *T. marneffei* infection and mechanistic studies are required. Endemic mycoses have not been reported in patients with CGD ([@B72]), so it appears that defective oxidative burst *per se* is not sufficient to cause an increased risk to dimorphic fungi, suggesting that other mechanisms of phagosomal killing may compensate for the lack of NADPH oxidase activity in eliminating these pathogens in the cytosolic compartment.

An algorithmic approach in history taking, targeted physical examination and stepwise immunological investigations will be helpful to assist clinicians in recognizing and diagnosing PIDs in patients with talaromycosis who are HIV-negative. Flow cytometric evaluation of CD40L expression and STAT1 phosphorylation is simple and rapid, with a turnaround time of less than 1 day to obtain a result that can provide important diagnostic information that guides treatment and genetic confirmation. STAT1 phosphorylation serve as a functional test of cellular responses mediated by type I (IFN-α/β) and type II (IFN-γ) IFNs. Flow cytometry-based STAT1 functional study has been described by Mizoguchi et al. ([@B73]) and Bitar et al. ([@B74]) as a rapid screening method to facilitate the diagnosis of CMC caused by GOF STAT1, which is characterized by STAT1 hyperphosphorylation in response to IFN-α or IFN-γ stimulation, and delayed dephosphorylation in the presence of staurosporine. Absence of STAT1 phosphorylation in response to IFN-γ but present in IFN-α stimulation suggests IFN-γ receptor deficiency. Impaired or absent STAT1 phosphorylation in response to both IFN-α and IFN-γ suggest loss-of-function STAT1 defect, and possibly JAK1 defect ([@B75]). Such functional defects, if present, should be confirmed by gene sequencing. If these tests are unrevealing, genetic defects of other molecules involved in IFN-γ production (IL12B, IL12Rβ1, TYK2, RORγ, ISG15, NEMO) or signaling pathway downstream to IFN-γ (GATA2, IRF8) should be considered ([@B76]), given the central importance of IFN-γ in host defense against *T. marneffei*. Considering the broad diagnostic possibilities, it would be reasonable to proceed with whole exome sequencing to identify the causative gene mutations. It is likely that increased awareness and improved diagnostics will unveil more PIDs underlying HIV-negative talaromycosis and other endemic mycoses, which will in turn advance our understanding about human immune response against this distinctive group of pathogenic fungi.
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